Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Agent Orange Exposure & Prostate Ca Outcomes

J Urol; ePub 2019 Jan 8; Etheridge, et al

In a large cohort of Veterans Affairs (VA) patients, Agent Orange exposure was associated with a decreased risk of death in men receiving androgen deprivation therapy (ADT) for advanced prostate cancer. Patients were diagnosed with prostate cancer from 2000 to 2008 with follow-up through May 2016. Clinical, pathological and demographics variables were compared by Agent Orange exposure. Associations of Agent Orange with overall survival, skeletal-related events, and cancer-specific survival were performed using adjusted Cox proportional hazard models after IPSW adjustment. Researchers found:

  • 87,344 patients were identified.
  • 3,475 Agent Orange exposed patients were younger, had lower prostate specific antigen, and were more likely to receive local therapy and chemotherapy than the 83,869 nonexposed patients.
  • After adjustment, Agent Orange exposure was associated with improved overall survival, but no difference was observed in the risk of skeletal-related events or cancer-specific survival.


Etheridge T, Liou JI, Downs TM, Abel EJ, Jarrard DF, Richards KA. The impact of Agent Orange exposure on prostate cancer outcomes. [Published online ahead of print January 8, 2019]. J Urol. doi:10.1016/j.juro.2018.10.005.